Share Name Share Symbol Market Type Share ISIN Share Description
Kromek LSE:KMK London Ordinary Share GB00BD7V5D43 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25p -1.02% 24.375p 24.00p 24.75p 24.75p 24.25p 24.625p 390,617 15:48:52
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 9.0 -3.8 -1.8 - 63.14

Kromek (KMK) Latest News

More Kromek News
Kromek Takeover Rumours

Kromek (KMK) Share Charts

1 Year Kromek Chart

1 Year Kromek Chart

1 Month Kromek Chart

1 Month Kromek Chart

Intraday Kromek Chart

Intraday Kromek Chart

Kromek (KMK) Discussions and Chat

Kromek Forums and Chat

Date Time Title Posts
23/10/201710:36Kromek Group PLC1,866
21/8/201710:01Kromek Group (KMK) - Overvalued AIM mugging181

Add a New Thread

Kromek (KMK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2017-10-23 15:48:3824.4065,00015,860.00OK
2017-10-23 15:15:5624.0010,0002,400.00O
2017-10-23 15:02:5424.131,000241.25O
2017-10-23 14:50:1024.0019,1774,602.48O
2017-10-23 14:49:0624.0012,0002,880.00O
View all Kromek trades in real-time

Kromek (KMK) Top Chat Posts

Kromek Daily Update: Kromek is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker KMK. The last closing price for Kromek was 24.63p.
Kromek has a 4 week average price of 22.88p and a 12 week average price of 22.88p.
The 1 year high share price is 36.75p while the 1 year low share price is currently 18.50p.
There are currently 259,015,618 shares in issue and the average daily traded volume is 301,837 shares. The market capitalisation of Kromek is £63,135,056.89.
basingblue: I guess there's one positive at the moment, the directors haven't been selling...yetI bet the major shareholder is pulling his hair thou and can't b happy with the share price
jpi_jason: At a guess Chimers maybe disappointed, as I'm to be honest with Kromek, I sold some Friday and yesterday, leaving just 30k shares, tried to sell this morning before the drop but would not let me do it in one go, which wasn't the case on the other two trades, I guess there's not much appetite from the small investor so no takers so left it, only to see further drop.Going to be hard for further recommendations until there is contract news, plenty of hope, ambition etc coming out from them, visit of trump to eu RNS , target markets in the tens of millions etc etc, but I think they've used all that up for now, but they released an RNS step change mentioned and we all had hopes of an explosion in price based on their confidence. Well we have only got is to see the share price fall back, and the mm's can play with this share as they try and generate a buyers and sellers market,.I'll still hold on to my holding for now, and see what occurs this week, but will only buy back when news flow starts, or there's a good volume turn over.Good luck to all
bapodra_investments: * The share price held up remarkably well considering it was down 8% - 10% in the morning. * This shows great strength. * The weak holders or traders have most probably exited. * The long trend is still in tact from a trend following perspective. PRICE ACTION. * The volume is healthy. VOLUME. * Contract wins are still to be announced going forwards so any buying now from retail institutions or large private buyers will accelerate the share price upwards for Kromek.
chimers: Shares of Kromek (LSE: KMK) have enjoyed a strong run this year, rising from 22.5p to a recent high of 36p. The company today released its results for its financial year ended 30 April and with the shares down 8.6% on yesterday’s close, this is a stock that is interesting me at a current price of 33p. Ramping up revenues Kromek is a radiation detection technology company focused on the medical, security screening and nuclear markets. It said 2016/17 was “another year of good progress and ramp-up in commercial activities with revenue growth driven by higher product sales across [its] three key target markets.” Revenue for the year increased 7.5% to £9m but 2017/18 will see a step change as revenue comes through on large-scale contracts that have been secured over the last 24 months. Management said: “The group expects to report year-on-year revenue growth of approximately 40%, in line with market expectations.” So we’re looking at about £12.6m. Kromek isn’t currently profitable, reporting a £3.1m bottom-line loss today, having expensed £3.5m of research costs for products and platforms that it said are “linked to existing contract deliverables and significant future revenue opportunities.”; The company had cash of more than £20m on its balance sheet at year-end (thanks to a fundraising in January) and has a good number of institutional investors on its shareholder register. While the cash pile means I’m unconcerned by Kromek’s current lossmaking status, it also means I have to value it on revenue rather than profit at this stage. Valuation At the current share price of 33p, the market capitalisation is £85m, so the stock trades at 6.8 times next year’s guided revenue of £12.6m. This looks an enticing multiple to me for an early-growth business, whose advanced patent-protected technologies are gaining increasing traction in the attractive medical, security screening and nuclear markets.
shrewdmole: Hi mike I'm very happy with Opti as despite the range bound share price it's all dropping into place. I have 3 core holdings in Kmk, Trin and Opti. Kmk and Opti should see huge revenue growth and are huge companies in the making of your prepared to be patient. Trin has been refinanced and is probably on a pe of about 2 at the moment!! Other than that I'm not really messing with other stocks. I can see fireworks coming here as I'm pretty sure there's a big buyer in the background. Sm
chimers: If you subscribe to the Investors Chronicle you will get live info like this which is now a week old. " Funded for explosive growth Another good example is Sedgefield-based Kromek (KMK:31.5p), a radiation detection technology company focused on the medical, security and nuclear markets. I had been patiently monitoring the company for some time, noting a raft of contract wins, but what prompted me to recommend buying the Aim-traded shares at 25p in late February was news of an oversubscribed placing and open offer which raised £20m ('Follow the smart money', 27 Feb 2017). It was an unusual fundraise as Kromek didn't need the money, but tapped shareholders to strengthen its position when negotiating contracts with government bodies and original equipment manufacturer (OEM) customers who had concerns about the company's financial strength and ability to supply significant quantities of its core cadmium zinc telluride (CZT) technologies. It's a hot area to be operating in given the geopolitical backdrop and heightened risk of terrorism. In fact, Kromek revealed this week that its next generation standalone radiation detector was deployed by the European Commission Counter Terrorism Unit during the NATO Security Summit and the visit to Brussels last month of US President, Donald Trump. It's a strong stamp of approval for the company's technology and can only be supportive of Kromek's revenues ramping up sharply as more potential customers sign on the dotted line. Bearing this in mind, although analysts Hannah Crowe and Paul Hill at research firm Equity Development predict Kromek can lift revenues by more than a third to £12.5m in the financial year to end April 2018, prompting a move into cash profitability, only £2.24m of this sum is dependent on new shipments. That's because £7.2m of the £12.5m revenue forecast is backed fully by a flow-through of the order book, and a further £3m is supported by repeat or expected orders. It wouldn't take many new contracts to accelerate the move into profitability. Reassuringly, while I was on annual leave, Kromek announced in a pre-close trading update that "products continue to gain traction in all our business segments from the increasing adoption of CZT-based technology and other products. The company expects to continue to win new customers and, together with the momentum of contract wins, it expects a step change in revenue growth in the new financial calendar year." Equity Development's forecasts look on the money to me. In the circumstances, it's hardly surprising that Kromek's share price subsequently hit my 34p target price. That was the cue for some profit taking, but after consolidating gains the share price looks well placed once again to achieve that discounted cash-flow-based target price. Rated on 1.8 times book value of £44m, and with pro-forma net cash of £22m equating to 8.5p a share. I would run profits ahead of next month's results."
bapodra_investments: At around 29.75p share price the market cap for Kromek is around £77.4m. Chimers, in your opinion what would be a realistic share price for Kromek and a credible and realistic market cap? Is there any danger that some of the potential news is already priced in as the stock market works on around 6 month future discounting mechanism (it is looking ahead around six months).
bapodra_investments: I thought exactly the same that the market cap was way to high. However, with stocks like Kromek who have an edge and there is not as much competition and their products have USP's then it is not entirely unreasonable to see market caps such as with Kromek. It is based on high growth and huge potential. I accept that if Kromek does not deliver the necessary growth in turnover then the market cap would adjust based on falling share price as a result. Whilst the market thinks Kromek can deliver then the market cap will only increase as the share price increases. There could be some huge announcements by Kromek and there is a nice upward trend at present so would not want to miss out and be out of the share at this moment in time. Momentum is building.
bapodra_investments: I think once market sentiment gets behind Kromek then this should help increase volume and share price. The current political tensions around the world involving the US, Russia and North Korea can only help to enhance the credibility and enhance the need for some of Kromek's product offerings. They have raised £20m and have plenty of firepower and cash on the balance sheet. I am expecting some significant contract win RNS's from now till December 2017 and potential investors will rue the chance of not investing in today's prices. This is one of those rare Nano Cap shares that one can see in years to come being listed on the FTSE 350. It also has massive takeover potential. It is earning revenue unlike the majority of AIM shares. Imagine the share price if Kromek ever became profitable?
hyperboreus: Not wishing to comment on anything that has gone before but ST did in fact reply yesterday to patient_investor regarding Kromek in his comments section basically just reiterating his current stance on the Company: 1:17 PM on 11/4/2017 Hi Simon, Please could you provide your thoughts on KMK share price returning to 26.40p, a fall of some 30% since their inevitable spike in the aftermath of your tip? Do you still rate the shares a "strong buy"? Regards Patient SIMONTHOMPSON 1:36 PM on 11/4/2017 Patient I advised buying Kromek shares at 25p on Monday, 27 February after which almost 12 million shares traded in 689 bargains in the following two days. The weight of money continued to chase the shares and this meant that the share price moved up 36 per cent from 25.5p on the offer at 12pm on Monday 27 February to a high of 34.9p on Tuesday 7 March. In my analysis I stated that: "From my lens, the bottom is now in place and a break-out above the 25p resistance is highly likely, suggesting a sharp move to the 30p resistance level that halted progress last summer. Beyond that analyst's 34p a share price targets come firmly into play." I can't blame anyone for taking a 36 per cent profit in the space of a week. I would also mention that the Daily Telegraph subsequently tipped the shares which accentuated the rise and a fair amount of that buying was hot money, hence the subsequent fall. Nothing has changed in terms of the investment case as I still believe that 34p a share is fair value. I would flag up that subsequent to my article, on 24 March 2017, Berry Beumer, Chief Operating Officer of Kromek, purchased 80,000 Ordinary Shares at a price of 29.35 pence per share. Also, Kromek has also been awarded a contract, valued at $990k, by an existing US-based customer, a global leader in aerospace and defence technologies, for the upgrade of the Company's advanced security screening detectors that the customer has deployed since 2009. I believe the shares rate a buy at 26p. I hope this clarifies matters. Best wishes
Kromek share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20171024 00:29:34